Treatment Options for Patients with Non-Small Cell Lung Cancer and Liver Metastases

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2024 Dec 27

PMID 39727930

Authors

Vesna Ceriman Krstic

Natalija Samardzic

Milija Gajic

Milan Savic

Biljana Seha

Marina Roksandic Milenkovic

Dragana Jovanovic

Affiliations

Soon will be listed here.

Abstract

Lung cancer represents the most common cause of cancer-related death. Patients with non-small cell lung cancer (NSCLC) and liver metastases have worse prognosis, with an overall survival (OS) from three to six months. The majority of them have a poor response to chemotherapy, and the data are controversial regarding the response to immunotherapy. This could be because the liver is considered to be an immune-tolerant organ, which is characterized by T-cell anergy and immunosuppressive signals. This review evaluates current treatment options for patients with NSCLC and liver metastases. Combination therapies might be a better treatment option for this subgroup of patients. The addition of radiotherapy to immunotherapy could also be an option in selected patients. The resection of single liver metastasis should also be considered.

References

Gutiontov S, Turchan W, Spurr L, Rouhani S, Chervin C, Steinhardt G . CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021; 11(1):20059. PMC: 8501138. DOI: 10.1038/s41598-021-99524-1. View

Zhu L, Yu X, Tang X, Hu C, Wu L, Liu Y . Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer. Chin Med J (Engl). 2024; 137(9):1019-1032. PMC: 11062672. DOI: 10.1097/CM9.0000000000002981. View

Mendez Romero A, Schillemans W, van Os R, Koppe F, Haasbeek C, Hendriksen E . The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases. Int J Radiat Oncol Biol Phys. 2021; 109(5):1377-1386. DOI: 10.1016/j.ijrobp.2020.11.045. View

Botticelli A, Cirillo A, Scagnoli S, Cerbelli B, Strigari L, Cortellini A . The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. Vaccines (Basel). 2020; 8(2). PMC: 7349154. DOI: 10.3390/vaccines8020203. View

Silva L, da Silva G, Bergmann A, Costa G, Zamboni M, Thuler L . Impact of different patterns of metastasis in non-small-cell lung cancer patients. Future Oncol. 2021; 17(7):775-782. DOI: 10.2217/fon-2020-0587. View

Maugeais M, Peron J, Dalle S, Boespflug A, Duruissaux M, Corbaux P . Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines. 2023; 11(1). PMC: 9855949. DOI: 10.3390/biomedicines11010083. View

Chen B, Song Y, Zhan Y, Zhou S, Ke J, Ao W . Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway. Cancer Lett. 2022; 543:215783. DOI: 10.1016/j.canlet.2022.215783. View

Huang Y, Zhu L, Guo T, Chen W, Zhang Z, Li W . Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis. Hum Vaccin Immunother. 2020; 17(5):1278-1287. PMC: 8078650. DOI: 10.1080/21645515.2020.1823779. View

Liao Y, Fan X, Wang X . Effects of different metastasis patterns, surgery and other factors on the prognosis of patients with stage IV non-small cell lung cancer: A Surveillance, Epidemiology, and End Results (SEER) linked database analysis. Oncol Lett. 2019; 18(1):581-592. PMC: 6546983. DOI: 10.3892/ol.2019.10373. View

10.

Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N . Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. Clin Lung Cancer. 2019; 20(6):e601-e608. DOI: 10.1016/j.cllc.2019.06.020. View

11.

Nagashima A, Abe Y, Yamada S, Nakagawa M, Yoshimatsu T . Long-term survival after surgical resection of liver metastasis from lung cancer. Jpn J Thorac Cardiovasc Surg. 2004; 52(6):311-3. DOI: 10.1007/s11748-004-0050-y. View

12.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N . Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer. Anticancer Res. 2018; 38(8):4723-4729. DOI: 10.21873/anticanres.12779. View

13.

Yin Q, Dai L, Sun R, Ke P, Liu L, Jiang B . Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients with Liver Metastases: A Network Meta-Analysis of Nine Randomized Controlled Trials. Cancer Res Treat. 2021; 54(3):803-816. PMC: 9296924. DOI: 10.4143/crt.2021.764. View

14.

Nogami N, Barlesi F, Socinski M, Reck M, Thomas C, Cappuzzo F . IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. J Thorac Oncol. 2021; 17(2):309-323. DOI: 10.1016/j.jtho.2021.09.014. View

15.

Xie M, Li N, Xu X, Xu Y, Li H, Zhu L . The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study. Cancers (Basel). 2022; 14(17). PMC: 9454794. DOI: 10.3390/cancers14174333. View

16.

Matsumoto H, Kobayashi N, Somekawa K, Fukuda N, Kaneko A, Kamimaki C . Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. Thorac Cancer. 2021; 13(2):228-235. PMC: 8758435. DOI: 10.1111/1759-7714.14252. View

17.

Wu K, Tsai M, Yang C, Chang W, Hung J, Yen C . Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer. 2015; 88(2):187-94. DOI: 10.1016/j.lungcan.2015.02.012. View

18.

Ying K, Zou L, Wang D, Wang R, Qian J . Co-mutation of TP53 and TTN is Correlated with the Efficacy of Immunotherapy in Lung Squamous Cell Carcinoma. Comb Chem High Throughput Screen. 2023; 27(18):2699-2711. DOI: 10.2174/0113862073246841230922052004. View

19.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA Oncol. 2019; 5(10):1411-1420. PMC: 6659167. DOI: 10.1001/jamaoncol.2019.2187. View

20.

Hakoda H, Sekine Y, Ichimura H, Ueda K, Aoki S, Mishima H . Hepatectomy for rapidly growing solitary liver metastasis from non-small cell lung cancer: a case report. Surg Case Rep. 2019; 5(1):71. PMC: 6497696. DOI: 10.1186/s40792-019-0633-6. View